Evercrisp Biosciences is innovating at the molecular level to enable precise, safe, and scalable delivery of genetic therapies into target tissues. Evercrisp applies proprietary technologies from world-renowned scientific founders to design miniproteins that can access brain, kidney, muscle, and other tissues previously unreachable by genetic medicines. Evercrisp miniproteins are “self-delivering” – they do not require assisted delivery via LNPs, viral vectors, or other vehicles that can trigger immune responses.
Company Details
- Employees
- 20
- Founded
- 2021
- Address
- 2630 Bancroft Way, Berkeley,california 94720,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.evercrispbio.com
- HQ
- Berkeley, California
Evercrisp Biosciences Questions
Evercrisp Biosciences's website is http://www.evercrispbio.com
Evercrisp Biosciences's LinkedIn profile is https://www.linkedin.com/company/evercrisp-biosciences
Evercrisp Biosciences has
20 employees.
View email and phone details for 20
employees at Evercrisp Biosciences.
Evercrisp Biosciences's industry is
Biotechnology Research
Evercrisp Biosciences's top competitors are
Shinobi Therapeutics,
Cionic,
Structure Therapeutics,
Vilya,
Rezo Therapeutics,
Pattern Biosciences,
Montara Therapeutics, Inc.,
Moonwalk Biosciences,
Aralez Bio,
Kimia Therapeutics.
Evercrisp Biosciences's categories are Biotechnology Research
Evercrisp Biosciences's founding year is 2021
